What is the place of teicoplanin and linezolid in the treatment of prosthetic joint infections? [2]

Clinical Microbiology and Infection

Volumn 12, Issue 12, 2006, Pages 1241-1242

  Tattevin, Pierre ^a   Arvieux, C ^a   Michelet, C ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCLOXACILLIN; LINEZOLID; METICILLIN; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; BLOOD TOXICITY; CLINICAL PROTOCOL; COAGULASE NEGATIVE STAPHYLOCOCCUS; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG INDICATION; DRUG USE; HUMAN; LETTER; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROSTHESIS INFECTION; SEPSIS;

EID: 33751099040     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2006.01560.x     Document Type: Letter

References (10)

1. Barberan J. Management of infections of osteoarticular prosthesis. Clin Microbiol Infect 2006; 12 (suppl 3): 93-101.
2. Robert J, Bismuth R, Jarlier V. Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: A 20 year study in a large French teaching hospital, 1983-2002. J Antimicrob Chemother 2006; 57: 506-510.
3. Linares J. The VISA/GISA problem: Therapeutic implications. Clin Microbiol Infect 2001; 7 (suppl 4): 8-15.
4. Trueba F, Garrabe E, Hadef R et.al. High prevalence of teicoplanin resistance among Staphylococcus epidermidis strains in a 5-year retrospective study. J Clin Microbiol 2006; 44: 1922-1923.
5. Odenholt I, Lowdin E, Cars O. In vitro studies of the pharmacodynamics of teicoplanin against Staphylococcus aureus, Staphylococcus epidermidis and Enterococcus faecium. Clin Microbiol Infect 2003; 9: 930-937.
6. Calain P, Krause KH, Vaudaux P et.al. Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections. J Infect Dis 1987; 155: 187-191.
7. Gilbert DN, Wood CA, Kimbrough RC. Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection. The Infectious Diseases Consortium of Oregon. Antimicrob Agents Chemother 1991; 35: 79-87.
8. Murray BE, Nannini EC. Glycopeptides (vancomycin and teicoplanin), streptogramins (quinupristin-dalfopristin), and lipopeptides (daptomycin). In: Mandell GL, Bennett JE, Dolin R, eds, Principles and practice of infectious diseases, 6th edn, vol. 1. Philadelphia, PA: Churchill Livingstone, 2005; 417-434.
9. Halpern M. Linezolid-induced pancytopenia. Clin Infect Dis 2002; 35: 347-348.
10. Bishop E, Melvani S, Howden BP, Charles PG, Grayson ML. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: A proposed protocol for monitoring therapy in complex patients. Antimicrob Agents Chemother 2006; 50: 1599-1602.